KUN - CHINA SHENGHUO PHARMACEUTICA - A0MWBN - 500 Beiträge pro Seite

[BarfuSs]

Wer kennt dieses Unternehmen?

TagesChart


JahresChart


GruSs BarfuSs

[BarfuSs]

NEWS vom 04.09.2007 15:25

China Shenghuo Pharmaceutical Holdings, Inc. to Present at Roth 2007 New York Conference

KUNMING, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced that Lei Lan, Executive Director of Sales, and Qionghua Gao, Chief Financial Officer, are scheduled to present at the Roth Capital Partners 2007 New York Conference.

The Roth Capital Partners 2007 New York Conference is a two-day event featuring presentations and one-on-one meetings with more than 230 small and microcap growth companies in a variety of industries.

Date: Thursday, September 6, 2007
Time: 12:00 p.m. EDT
Venue: The Westin New York at Times Square
Live webcast: http://www.wsw.com/webcast/roth13/csheng/


A replay of the webcast will be available for 90 days beginning the afternoon of the presentation.

About China Shenghuo Pharmaceutical Holdings, Inc.

Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the Company") is a leading specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine into 1,650 hospitals and 1,500 drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, the company's reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company's intellectual property rights, market acceptance of the company's products, changes in the laws of the People's Republic of China that affect the company's operations, any recurrence of severe acute respiratory syndrome or avian flu, the company's ability to obtain all necessary government certifications and/or licenses to conduct the company's business, development of a public trading market for the company's securities, cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the company's operations and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Ms. Gao Qionghua, CFO
China Shenghuo Pharmaceutical Holdings, Inc.
Tel: [phone]
Email: [e-mail]

Crocker Coulson, President
CCG Elite Investor Relations
Tel: [phone] (New York)
Email: [e-mail]

GruSs BarfuSs

[BarfuSs]

NEWS vom 13.09.2007 15:13

China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
KUNMING, China, Sept. 13 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced it began the full-scale launch of its 12Ways(R) Chinese herbal skin care products ("12Ways") on Sunday, September 9, 2007.

"We are excited about the launch of our 12Ways product line, and we expect it to be another profit driver in addition to our flagship product, Xuesaitong Soft Capsules, during the 2008 fiscal year," said Mr. Gui Hua Lan, China Shenghuo's Chairman and Chief Executive Officer.

The 12Ways series is based on the use of traditional Chinese herbs, such as Sanchi, Tuckahoe, and Salvia miltiorrhiza. The planned full-scale launch includes 34 products in seven categories, including: a group of Sanchi-based skin moisturizers; a Salvia-based fading cream; a skin lightener; Yunnan bamboo-based acne treatment; an anti-aging cream that utilizes eucommia ulmoide; sunscreen; and dietary supplements.

"Our 12Ways series contains natural elements and provides solutions for women who look for healthy beauty," Mr. Lan added.

12Ways caters to 25 to 40-year-old women, who are typically interested in products that are both effective and safe. China Shenghuo has set up three sales and marketing offices in Beijing, Guangzhou and Shanghai to better support sales in local regions.

The Company, which intends to distribute its 12Ways skin care products in major pharmacy chains in China, unveiled the new products at the "Forum of Marketing on Chinese Pharmaceutical Cosmetics" on Sunday, September 9, 2007 in Dongguan, Guangdong Province. The forum included presentations by Chinese pharmaceutical industry experts and members of China Shenghuo's management team. Major national pharmacy chains were invited to the forum, which was hosted by the South Pharmaceutical Economic Research Institute.

The Company previously marketed this new line only in its native Yunnan province. Sunday's event was 12Ways' first full-scale launch into a number of cities and provinces outside China Shenghuo's local region.

China Shenghuo hopes to open a number of retail specialty counters to offer its cosmetic products at pharmacies throughout Eastern China by the first half of 2008, eventually expanding its retail presence across China. Management believes this retail counter strategy will allow China Shenghuo to increase its brand recognition, as well as sell and market its newest cosmetics products developed using its expertise in traditional Chinese medicine.

About China Shenghuo Pharmaceutical Holdings, Inc.

Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the "Company") is a specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, the company's reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company's intellectual property rights, market acceptance of the company's products, changes in the laws of the People's Republic of China that affect the company's operations, the company's ability to obtain all necessary government certifications and/or licenses to open and operate retail specialty counters to offer its cosmetic products and conduct the company's business, cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the company's operations and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

China Shenghuo Pharmaceutical Holdings, Inc.
Ms. Gao Qionghua, CFO
Tel: [phone]
Email: [e-mail]

CCG Elite Investor Relations
Crocker Coulson, President
Tel: [phone] (New York)
Email: [e-mail]

GruSs BarfuSs

[BarfuSs]

und as noch


P/E ratio 31.95
Earnings Per Share 0.21
Shares Outstanding 19,579,000
Market Cap 196,768,950


GruSs BarfuSs

[BarfuSs]

Hallo,

SK 15,18$ +43,34% Volumen 3,487,800

Der Chart


Der GruSs
BarfuSs

[BarfuSs]

Nabent,

SK 14,99$ +3,74(+33,24%) Volumen 1,29 Mio.

Nacht BarfuSs

[BarfuSs]

Hallo,

RT 13,45 -10,21% Volumen 484,300
Wie gewonnen, so zerronen.

BarfuSs

[BarfuSs]

China Shenghuo Pharmaceutical Holdings, Inc.
Opens Showcase 12Ways(R)
Chinese Herbal Beauty Salon in OctoberLast update: 10/16/2007 9:00:00 AMKUNMING,

China, Oct 16, 2007 /Xinhua-PRNewswire-FirstCall via COMTEX/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company") (KUN), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced its showcase 12Ways(R) Chinese Herbal Beauty Salon ("Salon") debuted in Kunming, China, on October 10, 2007. Accented with traditional Chinese decor, the Company's first full-service Salon is located in Xiao Xi Men, one of the major commercial districts in Kunming, which attracts more than 400,000 people each day. Unlike China Shenghuo's previous salons, this centerpiece, free-standing store is the first of its salons to offer traditional Chinese medicine services. It is expected to be used as a training center in the future. The 12Ways Chinese Herbal Beauty Salon features more than 10 traditional Chinese medicine practitioners and beauticians skilled in a variety of services, including acupuncture, body massage, foot massage and other services. In the Salon, every customer has an advisor to track her improvement and give personal suggestions. The solutions provided by advisors include Chinese culture lectures, Chinese medicinal beauty treatment, cosmetics, dietary treatment, health food and proper physical exercises for each patron, who is looking for healthy beauty. All products used in the salon will be supplied by Shenghuo Cosmetics Company, a subsidiary of China Shenghuo Pharmaceutical. In addition, the professionals will instruct customers in the appropriate dietary supplements to treat any symptoms discovered during a traditional Chinese medical diagnosis. "We are very excited for the debut of the 12Ways Chinese Herbal Beauty Salon," said Mr. Gui Hua Lan, China Shenghuo's Chairman and Chief Executive Officer. "This new showroom furthers our strategy to fully introduce 12Ways products to our core consumers, women who are seeking healthy beauty." After the initial Salon opening in Kunming, the Company plans to expand the business into a larger region of China during the next three years by opening retail counters at major pharmacy chains. Management believes this retail counter strategy will allow China Shenghuo to increase its brand recognition, as well as sell and market its newest cosmetics products developed using its expertise in traditional Chinese medicine. 12Ways caters to modern women, who are typically interested in products that are both effective and safe. The name was inspired by Chinese tradition, which says the number 12 connotes harmony and good luck. China Shenghuo has set up three sales and marketing offices in Beijing, Guangzhou and Shanghai to better support sales in local regions.

[BarfuSs]

China Shenghuo Pharmaceutical Holdings, Inc. Announces Conference Call to Discuss Third Quarter FY 2007 ResultsLast update:
11/13/2007 9:00:00 AM

KUNMING, China, Nov 13, 2007 /Xinhua-PRNewswire-FirstCall via COMTEX/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company") (KUN), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced it will conduct a conference call at 8:00 a.m. EST on Friday, November 16, 2007, to discuss the Company's financial results for the third quarter, ended September 30, of its 2007 fiscal year. Hosting the call will be Feng Lan, Director and President, and Qionghua Gao, Chief Financial Officer. To participate in the event by telephone, please dial [phone] five to 10 minutes prior to the start time (to allow time for registration) and reference the conference ID 46154547. International callers should dial [phone] and reference the same passcode. A digital replay of the call will be available on Friday, November 16 at approximately 10:00 a.m. EST through Friday, November 23 at 12 p.m. EST. To listen to the replay, dial [phone] and enter the conference ID number 98064518. International callers should dial [phone] and enter the same conference ID number. The conference call will also be webcast live over the Internet and can be accessed by all interested parties at the company's Web site, . To monitor the live webcast, please visit the Company's Web site and click on the webcast link at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. An audio replay of the event will be archived on China Shenghuo's Web site, at .

[BarfuSs]

China Shenghuo Pharmaceutical Holdings, Inc. to Launch 12Ways(R) Advertisement on CCTV in January 2008
Last update: 12/6/2007 9:00:00 AM

KUNMING, China, Dec 06, 2007 /Xinhua-PRNewswire-FirstCall via COMTEX/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company") (KUN), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced it has won a bid to launch its new television commercial promoting China Shenghuo's 12Ways(R) Chinese Herbal Cosmetics on China Central Television ("CCTV"). This is the first time a Chinese herbal cosmetics manufacturer has won commercial airtime in CCTV's most popular time slot. Beijing Xinxin Changrong Advertising Co., Ltd. served as the agent for the bid. Under terms of the agreement, which runs from January 1, 2008, through December 31, 2008, China Shenghuo's 12Ways Chinese Herbal Cosmetics will be featured in a 15-second segment aired 10 times per day on CCTV Channels 1, 3 and 8. "We are excited to increase our customers' awareness of Chinese herbal cosmetics by launching the 12Ways television commercials on CCTV, which is well-recognized in China," said Mr. Gui Hua Lan, China Shenghuo's Chairman and Chief Executive Officer. "China's hosting of the 2008 Olympics will bring enormous attention to the event and the nation from all over the world. This provides us with an excellent opportunity to increase the public's awareness of 12Ways skin care, which is an essential part of the product line's success." CCTV is the national television network of the People's Republic of China. It features 15 channels with combined daily airtime of more than 200 hours and attracts more than 1 billion viewers, covering more than 90% of China's population. Following the Company's full-scale launch of its 12Ways series in September, China Shenghuo has opened more than 10 retail counters in pharmacies in Beijing, Shanghai, Zhejiang, Fujian and Sichuan provinces. China Shenghuo hopes to operate 100 retail counters by the end of 2008. 12Ways caters to modern women, who are typically interested in products that are both effective and safe. The name was inspired by Chinese tradition, which says the number 12 connotes harmony and good luck. China Shenghuo has set up three sales and marketing offices in Beijing, Guangzhou and Shanghai to better support sales in local regions.

About China Shenghuo Pharmaceutical Holdings, Inc. Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the "Company") is a leading specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, the company's reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company's intellectual property rights, market acceptance of the company's products, changes in the laws of the People's Republic of China that affect the company's operations, the company's ability to obtain all necessary government certifications and/or licenses to open and operate retail specialty counters to offer its cosmetic products and conduct the company's business, cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the company's operations and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

[BarfuSs]

RT 9,45$ +26,00% Vol. 776.600